E-mail Print PDF
Olorunseun  Ogunwobi

Olorunseun  Ogunwobi

Professor of Biology

Director, Hunter College Center for Cancer Health Disparities Research (CCHDR)

Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Office: Room 426 Belfer Research Building

413 East 69th Street

New York, NY 10021

Mail Box 180
Phone:  (212)-896-0447
Lab Web Site:


  • MBBS., 2000, College of Medicine, University of Ibadan, Nigeria
  • M.S., 2004, University of Hull, United Kingdom
  • Ph.D., 2007, University of East Anglia, United Kingdom
  • Post doc., 2007-2014, University of East Anglia/Virginia Commonwealth University/University of Florida

Research Interest:

  • Cancer Biology
    The overall goal of our laboratory is to elucidate the mechanisms of metastasis in solid cancers. Ongoing studies include examination of the role of circulating tumor cell biology and epigenetics in the metastasis of solid cancers. Also, our laboratory is investigating the biological mechanisms underlying the racial disparities in specific solid cancers. The cancer models we are currently focused on are hepatocellular carcinoma, pancreatic cancer, colon cancer, and prostate cancer.

Selected Publications:

  • Zambrano CN, Lu W, Johnson C, Beeber M, Panitz A, Ibrahim S, Fraser M, Ma GX, Navder K, Yeh M, Ogunwobi OO. Dietary behavior and urinary gallic acid concentration differences among underserved elder racial and ethnic minorities in New York City. Cancer Causes & Control. 2022, doi: 10.1007/s10552-022-01581-y.
  • Awah C, Winter J, Ogunwobi OO. Genome scale CRISPR Cas9a knockout screen reveals genes that control glioblastoma susceptibility to the alkylating agent temozolomide. All Life. 2022, 15 (1): 88–93, DOI:
  • Akingboye A, Mahmood F, Amiruddin N, Reay M, Nightingale P, Ogunwobi OO. Increased risk of COVID-19 related admissions in active solid organ cancer patients in the West Midlands region of the United Kingdom: A Retrospective cohort study. BMJ Open. 2021;11: e053352. DOI:
  • Awah C, Winter J, Mazdoom C, Ogunwobi OO. NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to Temozolomide (TMZ) via NELFB and RPS6KB2 interaction. Cancer Biology & Therapy. 2021, 27:1-11.
  • Naidoo M, Levine F, Gillot T, Orunmuyi AT, Olapade-Olaopa EO, Ali T, Krampis K, Pan C, Dorsaint P, Sboner A and Ogunwobi OO. MicroRNA-1205 regulation of FRYL in prostate cancer. Frontiers in Cell and Developmental Biology. 2021, 9:647485. DOI: 10.3389/fcell.2021.647485.
  • Asante-Asamani E, Pal G, Liu L, Ogunwobi OO. Prostac: a new composite score with potential predictive value in prostate cancer. Front. Oncol. 2021, 11:644665. DOI: 10.3389/fonc.2021.644665.
  • Levine F, Ogunwobi OO. Targeting PVT1 Exon 9 Re-Expresses Claudin 4 Protein and Inhibits Migration by Claudin—Low Triple Negative Breast Cancer Cells. Cancers 2021, 13 (5), 1046;
  • Beales ILP, Ogunwobi OO. Leptin activates Akt in oesophageal cancer cells via multiple atorvastatin-sensitive small GTPases. Molecular and Cellular Biochemistry 2021; doi: 10.1007/s11010-021-04067-8.
  • Ogunwobi OO, Segura MF. Editorial: PVT1 in cancer. Front. Oncol. 2020, 10: 588786; doi: 10.3389/fonc.2020.588786.
  • Ogunwobi OO, Mahmood F, Akingboye A. Biomarkers in Colorectal Cancer: Current Research and Future Prospects. Int. J. Mol. Sci. 2020, 21(15), 5311;
  • Huaman J, Ogunwobi OO. Circulating Tumor Cell Migration Requires Fibronectin Acting through Integrin B1 or SLUG. Cells 2020, 9(7), 1594;
  • Pal G, Di L, Orunmuyi A, Olapade-Olaopa EO, Qiu W, Ogunwobi OO. Population Differentiation at the PVT1 Gene Locus: Implications for Prostate Cancer. G3: Genes, Genomes, Genetics, 2020; 10 (7): 2257-2264.
  • Onagoruwa OT, Pal G, Ochu C, Ogunwobi OO. Oncogenic Role of PVT1 and Therapeutic Implications. Front. Oncol. 2020, 10:17, doi: 10.3389/fonc.2020.00017.
  • Alegbeleye BJ, Ogunwobi OO. Primary Diffuse Large B-Cell Lymphoma of the Breast: A Rare Case Report and Review of the Literature. International Journal of Scientific Advances. 2020, 1 (2): 79-86.
  • T.I. Shireman, A.C. Adia, Y. Tan, L. Zhu, J. Rhee, O.O. Ogunwobi, G.X. Ma, Online Versus In-Person Training of Community Health Workers to Enhance Hepatitis B Virus Screening Among Korean Americans: Evaluating Cost & Outcomes, Preventive Medicine Reports (2020), doi:
  • Pal G, Ogunwobi OO. Copy number - based quantification assay for non - invasive detection of PVT1 - derived transcripts. PLoS ONE. 2019, 14(12): e0226620.
  • Pal G, Huaman J, Levine F, Orunmuyi AT, Olapade-Olaopa EO, Onagoruwa OT, Ogunwobi OO. Long Noncoding RNA from PVT1 Exon 9 Is Overexpressed in Prostate Cancer and Induces Malignant Transformation and Castration Resistance in Prostate Epithelial Cells. Genes. 2019, 10(12), 964;
  • Harricharran T, Ogunwobi OO. Oxytocin and oxytocin receptor alterations decreased survival and increased chemoresistance in patients with pancreatic cancer. Hepatobiliary & Pancreatic Diseases International. 2020, DOI: 10.1016/j.hbpd.2019.12.002.
  • Anand P, Filipenko P, Huaman J, Lyudmer M, Hossain M, Santamaria C, Huang K, Ogunwobi OO, Holford M. Selective inhibition of liver cancer cells using venom peptide. Marine Drugs. 2019, 17(10), 587; Featured in PBS/NOVA’s “Beyond the Elements: Reactions”:
  • Zambrano C, Johnson C, Lu W, Beeber M, Panitz A, Wyka K, Ibrahim S, Fraser M, Bhimla A, Tan Y, Navder K, Yeh M, Ma GX, Ogunwobi OO. Dietary behavior and urinary gallic acid concentrations in older minority residents of East Harlem, New York City. Journal of Racial and Ethnic Health Disparities. 2020, 7, 217–223; DOI: 10.1007/s40615-019-00649-x.
  • Agrawal R, Chen M, Ogunwobi OO, Bukhari Z, Haseeb MA, Martello LA. EZH2 Downregulation Augments the Effect of Irradiation in Reducing Pancreatic Cancer Cell Proliferation In Vitro. Ann. Clin. Lab. Sci. 2020; 50(1):45–56.
  • Harricharran T, Ogunwobi OO. Emergence of neural regulatory mechanisms in carcinogenesis. World Journal of Clinical Oncology. 2019; 10 (8): 279-282.
  • Ogunwobi OO, Kumar A. Chemoresistance Mediated by ceRNA Networks Associated with the PVT1 Locus. Front Oncol 2019, 9: 834; doi: 10.3389/fonc.2019.00834.
  • Harricharran T, Ogunwobi OO. Oxytocin receptor genetic alterations in hepatocellular carcinoma. Springer Nature Comprehensive Clinical Medicine. 2019, 1(7), 523-526; doi: 10.1007/s42399-019-00085-2.
  • Huaman J, Naidoo M, Zang X, Ogunwobi OO. Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells. Cells 2019, 8, 618.
  • Derderian C, Orunmuyi AT, Olapade-Olaopa EO, Ogunwobi OO. PVT1 signaling is a mediator of cancer progression. Front. Oncol. 2019; 9: 502.
  • Halpern, M. T., Dodd, SJ, Fang, C. Y., Tan, Y., Zhu, L., Ogunwobi, O. O. & Ma, G. X. Evaluation of a transdisciplinary cancer research training program for under-represented minority students. Informing Science Institute. 2019: 99 -108;
  • Ogunwobi OO, Ma GX. SPEECH: Synergistic Partnership for Enhancing Equity in Cancer Health. Cancer Health Disparities 2019; 4: e1.e5. doi:10.9777/chd.2019.1012.
  • Ogunwobi OO, Dibba O, Zhu L, Ilboudo A, Tan Y, Fraser MA, Ma GX. Hepatitis B Virus Screening and Vaccination in First-Generation African Immigrants: A Pilot Study. Journal of Community Health 2019; 44 (6) 1037–1043;
  • Ogunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, Ma GX, Nguyen MT. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol 2019; 25(19): 2279-2293.
  • Gao C, Xiao G, Piersigilli A, Gou J, Ogunwobi O, Bargonetti J. Context Dependent Roles of MDMX (MDM4) and MDM2 in Breast Cancer Proliferation and Circulating Tumor Cells. Breast Cancer Research 2019; 21 (1): 5.
  • Lerman B, Harricharran T, Ogunwobi OO. Oxytocin and cancer: An emerging link. World J Clin Oncol 2018; 9(5): 74-82.
  • Lee M, Zhu L, Wang MQ, Wei Z, Tan Y, Nguyen MT, Ogunwobi OO, Ma GX. Psychosocial Predictors of HBV Screening Behavior among Vietnamese Americans. Am J Health Behav. 2017 Sep 1;41(5):561-570. doi: 10.5993/AJHB.41.5.5.
  • Luu HN, Lin H, Sørensen K, Ogunwobi OO, Kumar N, Chornokur G, Phelan CM, Jones D, Kidd L, Batra J, Yamoah K, Berglund A, Rounbehler RJ, Yang M, Lee SH, Kang N, Kim SJ, Park J, Di Pietro G. miRNAs associated with Prostate Cancer risk and progression. BMC Urology 2017;17(1):18. doi: 10.1186/s12894-017-0206-6.
  • Das DK, Ogunwobi OO. A novel microRNA-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer. RNA and Disease 2017; 4: e1503. doi: 10.14800/rd.1503.
  • Das DK, Ali T, Krampis K, Ogunwobi OO. Fibronectin and androgen receptor expression data in prostate cancer obtained from a RNA-sequencing bioinformatics analysis. Data in Brief, 2017, 11:131-135.
  • Das DK, Naidoo M, Ilboudo A, Park JY, Ali T, Krampis K, Robinson BD, Osborne JR, Ogunwobi OO. miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin. Experimental Cell Research. 2016; 348(2):190-200.
  • Spratt DE, Chan T, Waldron L, Speers C, Feng FY, Ogunwobi OO, Osborne JR. Racial/Ethnic Disparities in Genomic Sequencing. JAMA Oncol. 2016; 2(8):1070-4.
  • Das DK, Osborne JR, Park JY, Ogunwobi OO. miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer. Translational Oncology. 2016; 9(3): 236–241.
  • Ilboudo A, Chouhan J, McNeil BK, Osborne JR, Ogunwobi OO. PVT1 exon 9: a potential biomarker of aggressive prostate cancer? Int. J. Environ Res Public Health, 2015, in press.
  • Das DK, Durojaiye V, Ilboudo A, Naidoo MK, Ogunwobi OO. A "patient-like" orthotopic syngeneic mouse model of hepatocellular carcinoma metastasis. J Vis Exp, 2015; (104), e52858, doi:10.3791/52858.
  • Das DK, Naidoo MK, Ilboudo A, DuBois P, Durojaiye V, Liu C, Ogunwobi OO. Isolation and propagation of circulating tumor cells from a mouse cancer model. J Vis Exp, 2015; (104), e52861, doi: 10.3791/52861



Last Updated ( Wednesday, 28 September 2022 16:05 )